KR20230015397A - 호흡기도 면역병리상태를 위한 흡입 il-1 차단 치료 - Google Patents

호흡기도 면역병리상태를 위한 흡입 il-1 차단 치료 Download PDF

Info

Publication number
KR20230015397A
KR20230015397A KR1020227044455A KR20227044455A KR20230015397A KR 20230015397 A KR20230015397 A KR 20230015397A KR 1020227044455 A KR1020227044455 A KR 1020227044455A KR 20227044455 A KR20227044455 A KR 20227044455A KR 20230015397 A KR20230015397 A KR 20230015397A
Authority
KR
South Korea
Prior art keywords
nebulizer
rhil
nebulized
anakinra
cov
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227044455A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 에이. 링
린 에이. 바라노우스키
케이틀린 알. 크라이저
미쉘 팔라시오스
Original Assignee
알타반트 사이언시스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알타반트 사이언시스 게엠베하 filed Critical 알타반트 사이언시스 게엠베하
Publication of KR20230015397A publication Critical patent/KR20230015397A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020227044455A 2020-05-21 2021-05-20 호흡기도 면역병리상태를 위한 흡입 il-1 차단 치료 Withdrawn KR20230015397A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063028494P 2020-05-21 2020-05-21
US63/028,494 2020-05-21
US202063072895P 2020-08-31 2020-08-31
US63/072,895 2020-08-31
PCT/IB2021/000347 WO2021234457A1 (en) 2020-05-21 2021-05-20 An inhaled il-1 blockade treatment for respiratory tract immunopathology

Publications (1)

Publication Number Publication Date
KR20230015397A true KR20230015397A (ko) 2023-01-31

Family

ID=76807913

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227044455A Withdrawn KR20230015397A (ko) 2020-05-21 2021-05-20 호흡기도 면역병리상태를 위한 흡입 il-1 차단 치료

Country Status (9)

Country Link
US (1) US20230210768A1 (enExample)
EP (1) EP4153213A1 (enExample)
JP (1) JP2023526536A (enExample)
KR (1) KR20230015397A (enExample)
CN (1) CN116348144A (enExample)
AU (1) AU2021277585A1 (enExample)
CA (1) CA3178404A1 (enExample)
MX (1) MX2022014626A (enExample)
WO (1) WO2021234457A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022006636A (es) * 2019-12-02 2022-11-09 Altavant Sciences Gmbh Tratamiento de trastornos de las vías respiratorias bajas.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1565620A (zh) * 2003-06-09 2005-01-19 上海复旦张江生物医药股份有限公司 白细胞介素－1受体拮抗剂治疗非典型性肺炎的用途
HUE048024T2 (hu) * 2006-08-10 2020-05-28 Roy C Levitt Anakinra bronchiolitis obliterans szindróma kezelésében való alkalmazásra
MX2022006636A (es) * 2019-12-02 2022-11-09 Altavant Sciences Gmbh Tratamiento de trastornos de las vías respiratorias bajas.

Also Published As

Publication number Publication date
AU2021277585A1 (en) 2022-12-15
WO2021234457A1 (en) 2021-11-25
US20230210768A1 (en) 2023-07-06
JP2023526536A (ja) 2023-06-21
MX2022014626A (es) 2023-02-22
CN116348144A (zh) 2023-06-27
CA3178404A1 (en) 2021-11-25
EP4153213A1 (en) 2023-03-29

Similar Documents

Publication Publication Date Title
Kumar et al. Effects of anticytokine therapy in a mouse model of chronic asthma
KR20120131245A (ko) 기관지 감염의 치료 방법
US20110059044A1 (en) Method of treating pulmonary disease with interferons
CN110051627A (zh) 包含rpl554的液体吸入制剂
JPH09510434A (ja) 重症の急性膵炎を改善するインターロイキン−１レセプター拮抗薬
US20050220763A1 (en) Method of treating idiopathic pulmonary fibrosis with aerosolized IFN-gamma
Ferrati et al. Dosing considerations for inhaled biologics
US20220409627A1 (en) Treatment of lower airways disorders
KR20230015397A (ko) 호흡기도 면역병리상태를 위한 흡입 il-1 차단 치료
Siekmeier et al. Treatment of systemic diseases by inhalation of biomolecule aerosols
US20230037014A1 (en) Methods of preventing cancer metastasis
US11365248B2 (en) Formulation of tocilizumab and method for treating COVID-19 by inhalation
US20220339099A1 (en) Compositions of interleukin-1 receptor antagonist
HK40095595A (zh) 用於呼吸道免疫病理学的吸入性il-1阻滞治疗
CA2622987C (en) Method of treating pulmonary disease with interferons
JP7607939B2 (ja) 喘息を治療するための方法
US20100015062A1 (en) Method of treating pulmonary disease with interferons
WO2025245024A1 (en) Compositions comprising liothyronine and methods of making thereof
KR20230118167A (ko) 다목적 적용을 위한 제형
WO2024077042A2 (en) Il-1 receptor antagonist treatment for neutrophilic lung disease
WO2025072845A1 (en) Compositions and methods for alleviating pulmonary ailments
WO2022005321A1 (en) Inhaled tocilizumab for treating interleukin-6 related respiratory diseases
TW202241490A (zh) 用於治療氣喘之脂質運載蛋白突變蛋白乾粉配製物
US20210322309A1 (en) Inhalable Formulation of a Solution Containing Olodaterol
HK40070179A (en) Vasoactive intestinal peptide (vip) for use in the treatment of drug-induced pneumonitis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202